Study of Carboplatin/Paclitaxel in Combination With ABT-869 in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
This study is designed to determine the clinical efficacy and toxicity of ABT-869 in combination with carboplatin and paclitaxel in the treatment of subjects with advanced or metastatic NSCLC.
Advanced or Metastatic Non-Small Cell Lung Cancer
DRUG: ABT-869|DRUG: Placebo for ABT-869|DRUG: ABT-869|DRUG: Carboplatin|DRUG: Paclitaxel
Progression Free Survival (PFS), Disease Progression
Overall survival, best response rate, time to tumor progression, objective response rate, best percent change in tumor size, duration of response, Disease Progression|Survival Rate, 12 Months
This study is designed to determine the clinical efficacy and toxicity of ABT-869 in combination with carboplatin and paclitaxel in the treatment of subjects with advanced or metastatic NSCLC.